Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Charcoal - Kureha

Drug Profile

Charcoal - Kureha

Alternative Names: AST-120; Kremezin; Kremezin Fine Granules; MP-146; Zysa

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kureha Corporation
  • Developer Daiichi Sankyo Pharmaceutical (Shanghai); Kureha Corporation; Mitsubishi Tanabe Pharma Corporation; Ocera Therapeutics
  • Class Absorbents
  • Mechanism of Action NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pouchitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal failure
  • Discontinued Crohn's disease; Gastro-oesophageal reflux; Hepatic encephalopathy; Irritable bowel syndrome; Pouchitis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jan 2018 Launched for Renal failure in Japan (PO, Tablet)
  • 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt plc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top